Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy
Cancer Immunology, Immunotherapy · 2023-06 · 72 (6) · 1343-1353
DOI: 10.1007/s00262-022-03333-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 28.11.2022. Verfasst von Alexandre Poirier und 1 weiteren Autor:innen. Beteiligte Einrichtung: Goodman Cancer Institute, McGill University, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Dendritic cells have been at the forefront of cancer-immunotherapy research for over 2 decades. They elicited that attention by having an unprecedented capacity to mount T cells responses against tumors. However, the clinical use of DC-based vaccination against established malignancies has resulted in limited clinical benefits. Several factors are responsible for limiting the efficacy of DC-based immunotherapy, such as the harmful influence of the tumor microenvironment on DCs activity. New insights into the inner process of DC-mediated T cell activation have supported the development of new strategies that potentiate DCs-based therapies. Herein, we identify signaling cascades that have recently been targeted by small molecules and biologicals to promote the activation of monocyte-derived DCs and decrease their susceptibility to becoming tolerogenic. While Statins can markedly enhance antigen presentation, protein kinase inhibitors can be used to increase the expression of co-receptors and adhesion molecules. STAT3 and IDO can be modulated to limit the production of regulatory factors that work against differentiation and activation. The targeting of multiple pathways simultaneously has also been found to produce synergism and drastically enhance DCs activity. Some of these strategies have recently yielded positive results in clinical settings against established malignancies such as non-small cell lung cancer. The emergence of these approaches opens the door for a new generation of potent dendritic cell-based therapeutics to fight cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Goodman Cancer Institute, McGill University, Montréal, Québec, Canada.
- Department of Experimental Medicine, McGill University, Montréal, Québec, Canada.
- Goodman Cancer Institute, McGill University, Montréal, Québec, Canada. michel.tremblay@mcgill.ca.
- Department of Biochemistry, McGill University, Montréal, Québec, Canada. michel.tremblay@mcgill.ca.
- Faculty of Medicine, McGill University, Montréal, Québec, Canada. michel.tremblay@mcgill.ca.
- Rosalind and Morris Goodman Cancer Institute, McGill University, 1160 Pine Avenue West, Montréal, Québec, H3A 1A3, Canada. michel.tremblay@mcgill.ca.
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Poirier, A., & Tremblay, M. L. (2023). Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy. Cancer Immunology, Immunotherapy, 72(6), 1343-1353. https://doi.org/10.1007/s00262-022-03333-y
Vancouver
Poirier A, Tremblay ML. Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy. Cancer Immunology, Immunotherapy. 2023;72(6):1343-1353. doi:10.1007/s00262-022-03333-y
BibTeX
@article{Poirier2023,
author = {Poirier, Alexandre and Tremblay, Michel L},
title = {Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
volume = {72},
number = {6},
pages = {1343--1353},
doi = {10.1007/s00262-022-03333-y}
}
EUVIMED